Background: The association between lipoprotein(a) levels, apolipoprotein(a) size and the (TTTTA)(n) polymorphism which is located in the 5' non-coding region of the apo(a) gene was studied in 263 patients with severe coronary heart disease and 97 healthy subjects.
Methods: Lp(a) levels were measured by ELISA, apo(a) isoform size was determined by SDS-agarose gel electrophoresis, and analysis of the (TTTTA)(n) was carried out by PCR. For statistical calculation, both groups were divided into low (at least one apo(a) isoform with < or = 22 Kringle IV) and high (both isoforms with >22 KIV) apo(a) isoform sizes, and into low number (<10 in both alleles) and high number of (> or =10 at least one allele) TTTTA repeats.
Results: Lp(a) levels were higher (P=0.007), apo(a) isoforms size < or =22 KIV and TTTTA repeats > or = 10 were more frequent (P=0.007 and 0.01) in cases than in controls. Lp(a) levels were found to be increased with low apo(a) weight in both groups (both P<0.0001). In multivariate logistic regression analysis, only the Lp(a) levels (P=0.005) and (TTTTA)(n) polymorphism (P=0.002) were found to be significantly associated with CHD.
Conclusion: Nevertheless, these results indicate that in CHD patients the (TTTTA)(n) polymorphism has an effect on Lp(a) levels which is independent of the apo(a) size.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0009-8981(01)00500-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials.
JACC Adv
February 2025
Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.
Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials.
Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels.
Statins-Their Effect on Lipoprotein(a) Levels.
Rev Cardiovasc Med
January 2025
Department of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Lipoprotein(a) (Lp(a)) serum concentration plays a crucial role as a risk factor in cardiovascular diseases and is gaining more and more attention. Patients with elevated lipoprotein(a) levels are often prescribed statins as they also have high concentrations of low-density lipoprotein cholesterol (LDL-C). Statins are drugs that successfully decrease LDL-C, but their effectiveness in Lp(a) levels reduction is uncertain.
View Article and Find Full Text PDFAnalysis of Metabolic Risk Factors for Microcirculation Disorders Post-Percutaneous Coronary Intervention and Predictive Model Construction: A Study on Patients with Unstable Angina.
Rev Cardiovasc Med
January 2025
Department of Cardiology, The Second Affiliated Hospital of Xuzhou Medical University, 221000 Xuzhou, Jiangsu, China.
Background: This study aimed to analyze the metabolic risk factors for microcirculation disorders in patients with unstable angina (UA) after percutaneous coronary intervention (PCI), evaluating their predictive value for developing microcirculation disorders.
Methods: A single-center retrospective study design was used, which included 553 patients with UA who underwent PCI. The angiographic microcirculatory resistance (AMR) index was calculated based on coronary angiography data.
Sex-specific alterations in emotional behavior and neurotransmitter systems in LPA receptor-deficient mice.
Neuropharmacology
January 2025
Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina (IBIMA-Plataforma BIONAND), 29590 Málaga, Spain; Unidad de Gestión Clínica de Salud Mental, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain. Electronic address:
Lysophosphatidic acid (LPA) and the endocannabinoid system (ECS) are critical lipid signaling pathways involved in emotional regulation and behavior. Despite their interconnected roles and shared metabolic pathways, the specific contributions of LPA signaling through the LPA receptor to stress-related disorders remain poorly understood. This study investigates the effects of LPA receptor deficiency on emotional behavior and neurotransmitter-related gene expression, with a focus on sex-specific differences, using maLPA-null mice of both sexes.
View Article and Find Full Text PDFScreening for Subclinical Atherosclerosis in Patients with Familial Hypercholesterolemia: Insights and Implications.
J Clin Med
January 2025
Institute of Cardiology, Istanbul University-Cerrahpaşa, 34098 Istanbul, Türkiye.
: Familial hypercholesterolemia (FH) is a monogenic dyslipidemia that leads to early cardiovascular events. Subclinical atherosclerosis refers to the formation of atheromatous plaques in arterial beds before any clinical events. In our study, we investigated the presence, extent, and independent predictors of subclinical atherosclerosis among patients diagnosed with FH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!